Trials / Completed
CompletedNCT01458340
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 2 Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Proof-of-Concept Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 295 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-9855 | Once daily |
| DRUG | TD-9855 | Once daily |
| DRUG | Placebo | Once daily |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-10-01
- Completion
- 2013-11-01
- First posted
- 2011-10-24
- Last updated
- 2022-04-04
- Results posted
- 2022-03-14
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01458340. Inclusion in this directory is not an endorsement.